Acquired aplastic anemia following SARS-CoV-2 vaccination.
Eur J Haematol
; 109(2): 186-194, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-1861307
ABSTRACT
COVID-19 is a potential life-threatening viral disease caused by SARS-CoV-2 and was declared a pandemic by the WHO in March 2020. mRNA-based SARS-CoV-2 vaccines are routinely recommended in immune-compromised patients, including patients with AA, as these patients are at increased risk of contracting COVID-19 and developing a more severe course of disease. Between March 2021 and November 2021 relapse of AA occurred in four (age [median] 53 years, range 30-84 years) out of 135 patients currently registered at our department and two de novo cases of AA in temporal context to vaccination against SARS-CoV-2, were documented. Median time after first COVID-19 vaccination and relapse of AA was 77 days. All relapsed patients were vaccinated with the mRNA-based vaccine Comirnaty®. Relapse in two out of the four patients was refractory to CsA/eltrombopag, favoring IST with hATG/CsA or BMT, respectively. Our observations should prompt clinicians to take vaccine-induced relapse of AA or de novo AA after SARS-CoV-2 vaccination into account. Furthermore, careful clinical monitoring and vigilance for signs or symptoms that may indicate relapse of AA (e.g., bleeding complications) are indicated.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
/
Anemia, Aplastic
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Language:
English
Journal:
Eur J Haematol
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
Ejh.13788
Similar
MEDLINE
...
LILACS
LIS